NCT00436670View on ClinicalTrials.gov

Phase II Study to Evaluate the Efficacy of AMG 317

PHASE2CompletedINTERVENTIONAL

Enrollment

294

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

February 28, 2009

Conditions

Asthma

Interventions

BIOLOGICAL

AMG 317 75 mg

75 mg SC weekly injection

BIOLOGICAL

AMG 317 150 mg

150 mg SC once weekly injection

BIOLOGICAL

AMG 317 300 mg

300 mg weekly SC injection

BIOLOGICAL

Placebo

Placebo SC once weekly injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY